Greenberg Traurig Assists Enlivex Therapeutics with $24.75 Million in Financing
Enlivex Therapeutics Ltd. - Ordinary Shares (ENLV)
Company Research
Source: PR Web
MIAMI (PRWEB) March 26, 2020 Greenberg Traurig, P.A. Miami office Corporate Shareholders Robert L. Grossman and Drew M. Altman represented Enlivex Therapeutics (Nasdaq: ENLV), a clinical-stage immunotherapy company, in two registered direct offerings aggregating $24.75 in financing for the company. The Tel Aviv, Israel-based company intends to use the net proceeds from the offerings for clinical, regulatory, manufacturing, and research and development activities, potential acquisitions, and in-licensing, as well as for working capital and other general corporate purposes.On Feb. 26, Enlivex closed a registered direct offering to certain institutional investors of 1,000,000 ordinary shares of the company at a purchase price of $8.00 per share for aggregate gross proceeds of $8.0 million.On March 5, Enlivex closed a registered direct offering to certain accredited and healthcare-focused institutional investors of an aggregate of 2,093,750 ordinary shares of the company and warrants to
Show less
Read more
Impact Snapshot
Event Time:
ENLV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENLV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENLV alerts
High impacting Enlivex Therapeutics Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ENLV
News
- Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $13.00 price target on the stock.MarketBeat
- Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis [Yahoo! Finance]Yahoo! Finance
- Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ OsteoarthritisGlobeNewswire
- Trump's crypto advocacy steers businesses away from traditional treasury assets [Yahoo! Finance Canada]Yahoo! Finance Canada
- Trump's crypto advocacy steers businesses away from traditional treasury assets [Yahoo! Finance Canada]Yahoo! Finance Canada
ENLV
Analyst Actions
- 9/27/24 - HC Wainwright
ENLV
Sec Filings
- 12/11/24 - Form 6-K
- 12/3/24 - Form 6-K
- 11/29/24 - Form 6-K
- ENLV's page on the SEC website